康泰生物(300601.SZ)：预防慢性乙肝临床治愈人群HBsAg复阳的重组乙型肝炎疫苗获得药物临床试验批准通知书

Core Viewpoint - The company, Kangtai Biological (300601.SZ), has received approval from the National Medical Products Administration for its recombinant hepatitis B vaccine (yeast) to conduct clinical trials in a new target population, specifically for chronic hepatitis B patients who have achieved functional (clinical) cure [1] Group 1 - The newly approved clinical trial aims to prevent HBsAg reversion in patients who have achieved a functional cure for chronic hepatitis B [1] - The approval is based on compliance with the relevant requirements for drug registration as per the Drug Administration Law and Vaccine Administration Law of the People's Republic of China [1] - The clinical trial will focus on a specific population, indicating a targeted approach in the company's research and development strategy [1]